{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T02:20:23Z","timestamp":1649125223703},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1007\/s00105-005-0945-2","type":"journal-article","created":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T16:35:34Z","timestamp":1112373334000},"page":"478-479","source":"Crossref","is-referenced-by-count":3,"title":["Aktueller Stand der Therapie mit Clofazimin (Lampren\u00ae) bei Lepra, Erythema leprosum und anderen Dermatosen nach Abgabe des Medikamentes von Novartis an die WHO"],"prefix":"10.1007","volume":"56","author":[{"given":"C. H.","family":"Sunderk\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Lan Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"PEIWorkflow-105-56-5_2005-05-10_14-48-08_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1489\/0020-7349(2004)72<320:ACSBAD>2.0.CO;2","volume":"72","author":"Sales","year":"2004","unstructured":"Sales AM, Sabroza PC, da Costa Nery JA et al. (2004) A comparative study between 12 and 24-dose therapeutic regimens for multibacillary leprosy patients (2004). Int J Lepr Other Mycobact Dis 72:320\u2013323","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"PEIWorkflow-105-56-5_2005-05-10_14-48-08_CR2","unstructured":"Sunderk\u00f6tter C, Bonsmann G (2003) Cyclosporin A bei Pyoderma gangraenosum und Vaskulitiden. In: Mrowietz U (Hrsg) Cyclosporin in der Dermatologie. Thieme, Stuttgart, S 29\u201337"},{"key":"PEIWorkflow-105-56-5_2005-05-10_14-48-08_CR3","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1365-4362.1999.00755.x","volume":"38","author":"Welsh","year":"1999","unstructured":"Welsh O, Gomez M, Mancias C et al. (1999) A new therapeutic approach to type II leprosy reaction. Int J Dermatol 38:931\u2013933","journal-title":"Int J Dermatol"},{"key":"PEIWorkflow-105-56-5_2005-05-10_14-48-08_CR4","unstructured":"WHO (1998) WHO Expert Committee on Leprosy. TRS 874, Geneva"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-0945-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-005-0945-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-0945-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:05Z","timestamp":1558582625000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-005-0945-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1007\/s00105-005-0945-2","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}